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HYPERSOMNIA IN WHIPPLE DISEASE
Case report
Luís F. Maia1, Mónica Marta1, Vitor Lopes2, Nelson Rocha2, 
Carlos Lopes3, Antônio Martins-da-Silva1, Luís Monteiro1
ABSTRACT - Whipple disease (WD) is a rare systemic infection caused by Tropheryma whippelii. Neurological
involvement has been recognised in 40% of patients, either as initial manifestations or during the course
of the disease. We report on a 45 years-old man with WD with initial, persistent and irresistible episodes
of daytime somnolence. The patient was HLA-DQB1*0602 positive (genetic marker for narcolepsy). WD
diagnosis was suspected on clinical and MRI basis and confirmed by histological and immunohistochemi-
cal study of duodenal biopsy. Forty months later all clinical features improved, narcoleptic-like episodes
disappeared and cerebral MRI and CSF normalised. Longitudinal neurophysiological studies revealed per-
sistent sleep pattern abnormalities with sleep fragmentation, paucity of slow wave and of REM sleep. The
disruption of the hypocretin circuitry in the hypothalamic - diencephalic region triggered by the infection
was the probable cause of the hypersomnia and narcopleptic symptoms. WD should be added to the list
of causes of secondary hypersomnia.
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Hipersónia na doença de Whipple: relato de caso
RESUMO - A doença de Whipple (DW) é infecção sistémica rara causada pelo Tropheryma whippelii. Cerca
de 40% dos doentes apresentam envolvimento neurológico, seja como manifestação inicial da doença,
seja durante o seu curso. Apresentamos o caso de um homem de 45 anos com doença de DW com episó-
dios iniciais, persistentes e irresistíveis de sonolência durante a actividade diurna. O doente era positivo
para o HLA-DQB1*0602 (marcador genético de narcolepsia). A suspeita do diagnóstico de DW foi levan-
tada com base na clínica e RM e confirmada por estudo imunocitoquímico do material de biópsia jejunal.
Quarenta meses mais tarde, todas as manifestações clínicas melhoraram, os episódios narcolépticos desa-
pareceram, e a RM e o LCR normalizaram. Os estudos neurofisiológicos seriados do sono revelaram alter-
ações persistentes caracterizadas por fragmentação do sono, escassez de ondas lentas e sono REM. A per-
turbação do circuito da hipocretina na região hipotálamo-diencefálica, causada pela infecção, foi a causa
provável da hipersónia num doente geneticamente susceptível. A DW deve ser incluída nas causas de hiper-
sónia secundária.
PALAVRAS-CHAVE: doença de Whipple, hipersónia, teste de latências múltiplas, HLA (DQB1*0602).
When George H Whipple first described in 1907
the autopsy findings of a case of “intestinal lipody-
strophy” no neurological manifestations were report-
ed and pathology of central nervous system (CNS)
was not described. Whipple disease (WD) was born.
It is now believed that the CNS is the major extra-in-
testinal site of involvement1,2. Data in the literature
report a variable frequency of neurological sympto-
matology of 5-40% with only 5% with exclusive CNS
involvement1-4. WD is caused by Tropheryma whip-
pelii (TW) and it is generally accepted that both the
presence of the bacillus and the host response are
responsible for the clinical manifestations of WD1,2.
Classic symptoms and signs of neurological involve-
ment are: vertical ophthalmoplegia, segmental myo-
rhythmia, myoclonus, dementia and hypothalamic
manifestations such as hyperphagia and changes in
libido3,4. Sleep disturbances mimicking narcolepsy are
exceptional5.
We report the clinical, biochemical, brain imag-
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ing, HLA genetic characterization, polysomnograph-
ic findings and outcome of a patient with sudden
episodes of hypersomnia, in whom WD was diagnos-
ed by duodenal biopsy. To the best of our knowledge,
this the first description of a case in which frequent
episodes of irresistible daytime somnolence (resem-
bling narcolepsy) are the initial, predominant, and the
most disturbing presenting feature of cerebral WD. 
CASE
A 45 year-old man, stone-mason, previously healthy,
was admitted with a 6 months history of frequent episodes
of sudden daytime sleepiness occurring while working, eat-
ing meals or even during showering. It would be difficult
to wake him up and the irresistible urge to sleep was be-
coming increasingly frequent. Night time sleep was rest-
less, with periods of sleepwalking, witnessed in several occa-
sions by relatives. After daytime sleep periods a frontal hea-
dache was reported, lasting for about two hours. In the
course of the disease, the headache became generalized
and permanent. During this period the patient ate more
than usual and gained 10 kg, exhibiting decreased libido
and psychomotor slowness. He also reported in the past,
on direct inquiry, short periods of polyarthralgias. Neither
diarrhoea or other gastrointestinal symptoms were referred.
In the course of hospitalization the patient neurologic
status was characterized by: 1- hypothalamic-diencephalic
syndrome with frequent irresistible episodes of daytime
somnolence, hyperphagia, decreased libido and mild per-
sistent hyponatremia; 2- neuro-ophthalmologic syndrome
with apraxia of lateral gaze and supranuclear ophthalmo-
paresis; 3- myoclonic syndrome with neck and right arm
segmental myoclonus, perioral and left laterocervical myo-
rhythmia; 4- frontal lobe syndrome with apathy, lack of ini-
tiative and psychomotor slowness. Other medical systems
examination was normal.
Cerebrospinal fluid (CSF) analysis showed lymphocytic
pleocytosis (20 cells/µL; 77% lymphocytes, 10% monocytes,
13% polymorphonuclear leukocytes), normal glucose (0.60
g/L) and protein (0.27 g/L). His complete blood count, ery-
throcyte sedimentation rate, electrolytes, renal, hepatic
and thyroid function, B12 vitamin and folic acid level and
serum angiotensin conversion enzyme were normal. The
serological tests for HIV 1 and 2, syphilis, borrelia, herpes I
and II, Epstein Barr virus, cytomegalovirus, Mycoplasma and
legionella were negative for acute infection. 
Brain MR imaging showed hyperintense signal on T2
weighted images on the caudate head, frontal operculum,
insula, hipocampus, right amygdalo-hipocampal transition
and hypothalamo-diencephalic region. All these areas
enhanced after gadolinium injection (Fig 1).
Based on the presence of supranuclear ophthalmople-
gia, segmental myoclonus and sub-cortical dementia cere-
bral, WD was suspected, in spite of the absence of gastroin-
testinal symptoms. Histology of duodenal tissue showed a
lymphoplasmacytic inflammatory infiltrate with PAS posi-
tive staining histiocytes on optic microscopy and the iden-
tification of the characteristic rod-shape intracellular organ-
ism by electron microscopy (Fig 2). The same tissue tested
positive for anti-TWi antibodies by immuno-histochemical
Fig 1. MRI images after gadolinium contrast injection: patchy contrast enhanced lesions in
the insula and hippocampus in the right and in the hypothalamic-diencephalic region.
Fig 2. Electron microscopy: Intra-cellular rod-shaped T. Whippelii.
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analysis. Polymerase chain reaction (PCR) CSF analysis was
negative. All these data confirmed the clinical diagnosis of
WD. HLA studies reveal the presence of the DBQ1*0602 ha-
plotype. Hypocretin studies were not available. Antibiotic
treatment started with ceftriaxone IV and streptomycin IM
during 4 weeks followed by oral cotrimoxazole the follow-
ing 18 months 
During hospitalization and follow-up, sleep was stud-
ied seven times (summary of the results are on Table). Ini-
tially a daytime registration was unsuccessful because the
patient did not fall asleep. Only myoclonic jerks were re-
corded (Record 1, or R1, on Table). Three MSLT were per-
formed, two out of them followed the APSS Committee
Guidelines6. On first MSLT (R2) an irresistible sleep episode
occurred on Nap 3 (patient fall asleep on Sleep SII and re-
mains asleep until the end of MLST; no REM period was
present). Four weeks after started treatment a nocturnal
recording was performed preceded by a routine EEG at
waking period. On night sleep recording (R3) a marked dis-
ruption of sleep structure was evident: sleep SII predomi-
nant and loss of SWS with limited efficiency (46%). No REM
sleep was present. The MSLT on the following morning/day
(R4) did not record sleep. Thirty months later myoclonus
resolved and very significant regression of the dementia,
ocular apraxia and vertical ophthalmoparesis. Although
attenuated, rare episodes of hypersomnia still persisted.
At that time CSF and brain MRI studies were normal. In
spite of the clinical and laboratorial improvement, night
sleep recording (R5) showed almost total insomnia with
only short periods of SI-SII. Studies performed at 40 months
after disease beginning (R6 and 7) showed initial insomnia
(Sleep Latency 161 minutes) partial improvement of sleep
structure with very short SIV, better sleep efficiency (50%)
and incipient REM sleep. A new sleep feature was the
recording of more than 100 obstructive sleep apnoeas, with
RDI surpassing 16/hour without significant decrease on O2
saturation. The MSLT did not record sleep. The initial promi-
nent sleep features were the extended sleep latency, the
paucity of slow wave sleep and the sleep fragmentation
and absence of significant REM. Sleep improvement was
noted in the last and more recent nocturnal sleep study, in
which obstructive sleep apnoeas were recorded.
The patient give informed consent for publication of
the case.
DISCUSSION
Whipple disease is a rare systemic infectious dis-
order with prominent but not invariable gastrointes-
tinal involvement. In the present study the patient
with cerebral WD had a clinical picture of myoclonus,
segmental myorhythmias, supranuclear ophthalmo-
paresis, and sudden episodes of hypersomnia1,3,4. This
CNS multifocal involvement translated into signs and
symptoms suggesting WD prompted us to carry out
a duodenal biopsy which confirmed the clinical diag-
nosis. The peculiarity of this case is the diurnal irre-
sistible episodes of sleep resembling narcolepsy (but
without REM sleep episodes recorded in MSLT), as
the prominent and initial clinical feature. This is, to
our knowledge, for the first time described in detail
by longitudinal PSG records. In previous descriptions,
sleep disturbances in WD patients are just men-
tioned5,7,8. A case of persistent and prolonged insom-
nia, however, was recently studied in detail9. 
In our patient the episodes of irresistible sleep
Table. Main characteristics of all sleep (night and day recordings). Sleep time, sleep latency and total sleep time are in minutes.
Recording type Sleep Total sleep Sleep Sleep REM sleep and Respiratory Notes
(Record #) latency time efficiency structure REM latency dysfunction
Day recording nsr 0 0 nsr nsr No No sleep recorded 
(R 1)
MSLT 13’ Nap 3 na na na No REM No Continuous sleep SII
(R 2) on Nap 3 – Nap 4
Night sleep 344 300 46% SII and No REM No
(R 3) occasionally SIII
MSLT (R4), nsr 0 0 nsr nsr No No sleep recorded
affter R3
Night sleep nsr 0 0 Short periods No REM No Night Insomnia 
(R 5) SI- SII (short epochs of SI-SII)
Night sleep 161 328 50.2% SII-SIII, Few REM Yes: Sleep apnoea Total 100 apnoeas 
(R 6) occasionally SIV (RDI : Mean 16/H) (mean 02 Sat =95%)
MSLT (R 7) nsr 0 0 nsr nsr No No sleep recorded
after R6
nsr, no sleep recorded; na, not aplicable.
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were confirmed by witness (including video by
authors) and on MSLT, although without recording
of REM episodes, pointed to the diagnosis of “pos-
sible” narcolepsy10. However, REM episodes as seen
in classical forms could be absent in secondary narco-
lepsy11. Secondary narcolepsy is rare but is known to
occur in cerebral sarcoidosis, pituitary lesions, cran-
iopharyngiomas, strokes, multiple sclerosis, HIV ence-
phalopathy, arteriovenous malformations and tumo-
urs involving the posterior hypothalamus11,12. An ex-
ception is the anti-Ma2 associated encephalitis where
narcolepsy is frequent13. The fact that our patient is
HLA DQB1*0602-positive, a strong genetic marker
for narcolepy, suggests that, in an appropriate set-
ting, promoting the disruption of the hypocretin cir-
cuitry an unnoticed subclinical disease may be reve-
aled10,14. The clinical picture improved significantly
after antibiotic treatment. However, the last PSG (40
months later) showed a disturbed sleep structure
with sleep apnoea. 
It is generally accepted that the hypothalamus is
involved in the control of the circadian rhythm, via
the suprachiasmatic nucleus and their connections
including hypothalamic and diencephalic areas is rel-
evant to the wake-sleep cycle generation15,16. In our
patient the mechanism through which these sleep
disturbances occurred is speculative. However the
association of an genetic marker for narcolepsy (HLA-
DBQ1*0602 haplotype) and a disease involving the
hypothalamic diencephalic region may have triggered
the disruption of the neurobiological control of sleep-
wakefulness in a highly susceptible narcoleptic type
patient. After a follow-up period of more than three
years, the therapy induced a progressive and sus-
tained clinical improvement with disappearance of
all cerebral lesions seen on the first MRI. A satisfac-
tory evolution like that observed with our patient is
rare in CNS involvement of WD3,4.
In conclusion, clinical suspicion, confirmed by duo-
denal biopsy or PCR studies in the CSF, is the hallmark
of the diagnosis of cerebral WD, which should be
considered on the investigation of sleep disturbances,
particularly when associated to daytime somnolence
and narcolepsy-like attacks. 
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